312 related articles for article (PubMed ID: 3869739)
1. Prevalence of HTLV-III/LAV antibody in selected populations in Thailand.
Wangroongsarb Y; Weniger BG; Wasi C; Traisupa A; Kunasol P; Rojanapithayakorn W; Fucharoen S
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):517-20. PubMed ID: 3869739
[TBL] [Abstract][Full Text] [Related]
2. Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Mar; 35(10):152-5. PubMed ID: 3005822
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of antibodies to HTLV-III in AIDS risk groups in West Germany.
Erfle V; Hehlmann R; Mellert W; Krüger G; Seifried E; Heimpel H; Rasokat H; Lechler E; Holzer E; Hellstern P
Cancer Res; 1985 Sep; 45(9 Suppl):4627s-4629s. PubMed ID: 3860292
[TBL] [Abstract][Full Text] [Related]
4. HTLV-III infection in Canada in 1985.
Neumann PW; Benning BJ; Robinson DG; Gilmore N; O'Shaughnessy MV
CMAJ; 1986 Sep; 135(5):477-80. PubMed ID: 3461870
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of antibodies to AIDS-associated retrovirus in in- and out-patients in Japan.
Ikegami N
AIDS Res; 1986 Dec; 2 Suppl 1():S29-34. PubMed ID: 3103640
[TBL] [Abstract][Full Text] [Related]
6. HIV and HTLV-I antibody studies: pregnant women in the 1960s, patients with AIDS, homosexuals, and individuals with tropical spastic paraparesis.
Madden DL; Tzan NR; Roman GC; Detels R; Mundon FK; Fuccillo DA; Sever JL
Yale J Biol Med; 1987; 60(6):569-74. PubMed ID: 2893497
[TBL] [Abstract][Full Text] [Related]
7. [Prevalence of antibodies against HTLV-III in various regions in Switzerland].
Schüpbach J; Vogt M; Bhushan R; Lüthy R; Haller O; Joller H; Ferber T; Büchner S; Schuppli R; Schädelin J
Schweiz Med Wochenschr; 1985 Jul; 115(30):1048-54. PubMed ID: 2994208
[TBL] [Abstract][Full Text] [Related]
8. [Antibodies against human T-cell leukemia virus type III in acquired immunodeficiency syndrome and persistent lymphadenopathy].
Wernicke D; v d Helm K; Abb J; Eberle J; Zoulek G; Pleyl G; Deinhardt F; Riethmüller G; Ziegler-Heitbrock HW; Rieber EP
Dtsch Med Wochenschr; 1984 Nov; 109(45):1709-11. PubMed ID: 6094134
[TBL] [Abstract][Full Text] [Related]
9. HTLV-III: the etiologic agent of AIDS.
Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
[TBL] [Abstract][Full Text] [Related]
10. Detection of antibody to LAV/HTLV-III in sera from hemophiliacs in China.
Zeng Y; Fan J; Zhang Q; Wang PC; Tang DJ; Zhon SC; Zheng XW; Liu DP
AIDS Res; 1986 Dec; 2 Suppl 1():S147-9. PubMed ID: 3103638
[TBL] [Abstract][Full Text] [Related]
11. Occupational risk of the acquired immunodeficiency syndrome among health care workers.
McCray E
N Engl J Med; 1986 Apr; 314(17):1127-32. PubMed ID: 3485769
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of two ELISA kits for the demonstration of antibodies against LAV/HTLV-III].
Heinz FX; Kunz C; Barrett N
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Apr; 264(1-2):196-200. PubMed ID: 3307232
[TBL] [Abstract][Full Text] [Related]
13. AIDS and prevalence of antibody to human immunodeficiency virus (HIV) in high risk groups in Thailand.
Traisupa A; Wongba C; Taylor DN
Genitourin Med; 1987 Apr; 63(2):106-8. PubMed ID: 3646990
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological trends of AIDS in the United States.
Curran JW; Morgan WM; Starcher ET; Hardy AM; Jaffe HW
Cancer Res; 1985 Sep; 45(9 Suppl):4602s-4604s. PubMed ID: 2990692
[TBL] [Abstract][Full Text] [Related]
15. Milan as possible starting point of LAV/HTLV III epidemic among Italian drug addicts.
Lazzarin A; Crocchiolo P; Galli M; Uberti Foppa C; Caredda F; Re T; Moroni M
Boll Ist Sieroter Milan; 1987; 66(1):9-13. PubMed ID: 3304347
[TBL] [Abstract][Full Text] [Related]
16. Screening for AIDS.
Med Lett Drugs Ther; 1985 Mar; 27(684):29-30. PubMed ID: 2984526
[TBL] [Abstract][Full Text] [Related]
17. Specificity of human immunodeficiency virus (LAV/HTLV-III)-reactive antibodies in African sera from southeastern Tanzania.
Schüpbach J; Tanner M
Acta Trop; 1986 Sep; 43(3):195-206. PubMed ID: 2877546
[TBL] [Abstract][Full Text] [Related]
18. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
19. Update: Public Health Service workshop on human T-lymphotropic virus type III antibody testing--United States.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1985 Aug; 34(31):477-8. PubMed ID: 2991728
[TBL] [Abstract][Full Text] [Related]
20. Human T-lymphotropic virus type III/lymphadenopathy-associated virus antibody testing at alternate sites.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 May; 35(17):284-7. PubMed ID: 3010070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
